Trials / Withdrawn
WithdrawnNCT06308575
A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- M.D. Anderson Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
To learn if rivoceranib can help to control olfactory neuroblastoma. The safety of this drug in participants with olfactory neuroblastoma will also be studied.
Detailed description
Primary Objective: \- To assess the efficacy of rivoceranib in patients with R/M ONB Secondary Objective: * To estimate the median duration of response (DOR) * Time to response * To estimate the median progression-free survival (PFS) * To estimate the median overall survival (OS) * To assess safety of rivoceranib Tertiary Objective: \- To explore biomarkers that may predict response to therapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rivoceranib | Given by PO |
Timeline
- Start date
- 2024-11-01
- Primary completion
- 2024-11-05
- Completion
- 2024-11-05
- First posted
- 2024-03-13
- Last updated
- 2025-01-10
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06308575. Inclusion in this directory is not an endorsement.